Process for the prepartion of erlotinib

Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

Reexamination Certificate

active

07960545

ABSTRACT:
The present invention discloses an improved and novel process for the preparation of erlotinib (N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine) of formula (1), which comprises: (i) demethylation of commercially available 6,7-dimethoxy-4(3H)-quinazolinone of formula (8); acetylation using acetic anhydride; (iii) introduction of a leaving group at C-4 position in quinazolinone; (iv) condensation with 3-ethynylaniline to get novel compound of formula (12); (v) deacetylation to get novel dihydroxy compound of formula (13); and (vi) O-alkylation with 2-iodoethylmethyl ether to get the erlotinib base of formula (1). Erlotinib base is purified by recrystallization from ethyl acetate to get a HPLC purity of >99.5%. Salt formation of this base with hydrogen chloride gave pharmaceutically acceptable erlotinib hydrochloride of formula (1a) with a HPLC purity of >99.8%. Erlotinib hydrochloride is useful for the treatment of proliferative disorders, such as cancers, in humans.

REFERENCES:
patent: 5747498 (1998-05-01), Schnur et al.
patent: 6900221 (2005-05-01), Norris et al.
patent: WO 96/09294 (1996-03-01), None
patent: WO 96/30347 (1996-10-01), None
patent: WO 01/34574 (2001-05-01), None

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Process for the prepartion of erlotinib does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Process for the prepartion of erlotinib, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the prepartion of erlotinib will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2709629

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.